Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361900 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL16201691 | 0.99 | CNR2 (0.98) | CNR2CNR1 | |
| SCHEMBL16201689 | 0.99 | CNR2 (0.98) | CNR2CNR1 | |
| SCHEMBL29988966 | 0.99 | CNR2 (0.98) | CNR2CNR1 | |
| SCHEMBL29362566 | 0.99 | CNR2 (0.98) | CNR2CNR1 | |
| SCHEMBL11983320 | 0.96 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29375790 | 0.96 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL6325191 | 0.91 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL29988839 | 0.91 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL6324025 | 0.89 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | UNIVERSITAT DE BARCELONA (ES) | 2025-11-04 | — | — | US | claimed |
| EP-4041748-B1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | UNIV BARCELONA (ES) | 2024-05-01 | — | — | EP | claimed |
| CN-117815105-A | Cosmetic containing peptide composition and preparation method thereof | 刘加英 | 2024-04-05 | — | — | CN | claimed |
| US-11660283-B2 | Cannabinoid-containing composition | JOYN BOTANICALS LTD. (CA) | 2023-05-30 | — | — | US | claimed |
| CN-115144489-A | Application of virtual template molecularly imprinted polymer in detection of synthesized casitone drugs | 大连海事大学 | 2022-10-04 | — | — | CN | claimed |
| CN-114945353-A | Controlled release formulations of highly lipophilic physiologically active substances | 埃德先进药物输送技术有限责任公司 | 2022-08-26 | — | — | CN | claimed |
| CN-114929197-A | Controlled release formulations of highly lipophilic physiologically active substances | 埃德先进药物输送技术有限责任公司 | 2022-08-19 | — | — | CN | claimed |
| EP-4041748-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | Universitat de Barcelona (ES) | 2022-08-17 | — | — | EP | claimed |
| CN-114641486-A | For reducing CB1Peptide compounds of side effects of receptor agonists | 庞培法布拉大学 | 2022-06-17 | — | — | CN | claimed |
| EP-3897732-A1 | CANNABINOID-CONTAINING COMPOSITION | Joyn Botanicals Ltd. (CA) | 2021-10-27 | — | — | EP | claimed |
| US-20180311181-A1 | Modular Transdermal Delivery Systems for the Treatment of Insomnia and Anxiety | International Bioceutical Co. LLC (US) | 2018-11-01 | — | — | US | claimed |
| US-20180311180-A1 | Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation | International Bioceutical Co. LLC (US) | 2018-11-01 | — | — | US | claimed |
| US-20180296498-A1 | MODULAR TRANSDERMAL DELIVERY SYSTEM AND ASSOCIATED METHODS OF MANUFACTURE AND USE | International Bioceutical Co. LLC (US) | 2018-10-18 | — | — | US | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| EP-2733205-B1 | Corticospinal upper motor neurons, methods and compositions for differentiating neural stem cells by modulating CB1 cannabinoid receptor signaling and uses thereof | CENTRO DE INVESTIGACÍON BIOMÉDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS CIBERNED (ES) | 2018-01-10 | — | — | EP | claimed |
| WO-2017190249-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2017-11-09 | — | — | WO | claimed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | claimed |
| EP-1895960-A4 | TRANSDERMAL DELIVERY OF CANNABINOIDS | ALLTRANZ INC (US) | 2009-08-26 | — | — | EP | claimed |
| EP-1895960-A1 | TRANSDERMAL DELIVERY OF CANNABINOIDS | Alltranz, LLC (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2007001891-A1 | TRANSDERMAL DELIVERY OF CANNABINOIDS | ALLTRANZ, LLC (US) | 2007-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | CNR2, CNR1, OPRD1 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.